$6.03
Insights on Foghorn Therapeutics Inc
Revenue is down for the last 2 quarters, 17.47M → 5.76M (in $), with an average decrease of 67.0% per quarter
Netprofit is down for the last 2 quarters, -14.34M → -24.10M (in $), with an average decrease of 68.0% per quarter
In the last 1 year, Novo Nordisk A/s has given 44.3% return, outperforming this stock by 61.6%
In the last 3 years, Novo Nordisk A/s has given 242.1% return, outperforming this stock by 289.7%
3.4%
Downside
Day's Volatility :6.05%
Upside
2.74%
55.22%
Downside
52 Weeks Volatility :72.92%
Upside
39.52%
Period | Foghorn Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 18.0% | -0.5% | 0.0% |
6 Months | 68.44% | 5.9% | 0.0% |
1 Year | -17.28% | 3.1% | -1.9% |
3 Years | -44.01% | 14.2% | -21.8% |
Market Capitalization | 272.0M |
Book Value | - $1.83 |
Earnings Per Share (EPS) | -2.34 |
Wall Street Target Price | 13.75 |
Profit Margin | -288.17% |
Operating Margin TTM | -441.29% |
Return On Assets TTM | -19.53% |
Return On Equity TTM | -470.38% |
Revenue TTM | 34.2M |
Revenue Per Share TTM | 0.81 |
Quarterly Revenue Growth YOY | 37.9% |
Gross Profit TTM | -86.4M |
EBITDA | -104.5M |
Diluted Eps TTM | -2.34 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.13 |
EPS Estimate Next Year | -1.34 |
EPS Estimate Current Quarter | -0.76 |
EPS Estimate Next Quarter | -0.69 |
What analysts predicted
Upside of 128.03%
Sell
Neutral
Buy
Foghorn Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Foghorn Therapeutics Inc | 1.69% | 68.44% | -17.28% | -44.01% | -66.72% |
Moderna, Inc. | -0.45% | 20.22% | -27.91% | -35.9% | 341.66% |
Regeneron Pharmaceuticals, Inc. | -6.85% | 6.85% | 9.08% | 78.94% | 160.71% |
Novo Nordisk A/s | -7.1% | 22.03% | 44.33% | 239.61% | 408.97% |
Vertex Pharmaceuticals Incorporated | -4.18% | 5.53% | 20.27% | 79.84% | 136.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Foghorn Therapeutics Inc | NA | NA | NA | -2.13 | -4.7 | -0.2 | NA | -1.83 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.21 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.84 | 25.84 | 1.46 | 45.15 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.75 | 46.75 | 2.4 | 3.36 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.57 | 28.57 | 0.53 | 16.72 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Foghorn Therapeutics Inc | Buy | $272.0M | -66.72% | NA | -288.17% |
Moderna, Inc. | Buy | $40.3B | 341.66% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.6B | 160.71% | 25.84 | 30.14% |
Novo Nordisk A/s | Buy | $559.8B | 408.97% | 46.75 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $102.7B | 136.07% | 28.57 | 36.68% |
Flagship Ventures Management, Inc.
FMR Inc
Raymond James & Associates
Euclidean Capital LLC
BlackRock Inc
Vanguard Group Inc
Foghorn Therapeutics Inc’s price-to-earnings ratio stands at None
Read Morefoghorn therapeutics inc., a biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. the company uses its proprietary gene traffic control platform to identify, validate, and potentially drug targets within the system. it is developing fhd-286, a small-molecule enzymatic inhibitor of brg1 and brm for the treatment of acute myeloid leukemia and uveal melanoma; and fhd-609, a small molecule protein degrader of brd9 to treat patients with synovial sarcoma. the company is also developing preclinical and discovery programs, including selective brm targeting non-small-cell lung cancer; and selective arid1b modulators for bladder, ovarian, and endometrial cancer. it has a collaboration with merck sharp & dohme corp. to discover and develop novel oncology therapeutics against a transcription factor target. the company was founded in 2015 and is headquartered in cambridge, massachusetts.
Organization | Foghorn Therapeutics Inc |
Employees | 116 |
CEO | Mr. Adrian H. B. Gottschalk |
Industry | Health Technology |